IGF-1 LR3 — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

IGF-1 LR3

Also known as: Long R3 IGF-1, LR3 IGF-1, LR3-IGF-1, Long R3 Insulin-Like Growth Factor 1, Long arginine 3 IGF-1, LR3-IGF-I, IGF-1 Long R3, IGF1-LR3, LONG R3 IGF-I

IGF-1 analogue / Insulin-like growth factor analogue

Research chemicalLast updated: October 19, 2026Based on 32 peer-reviewed studies

What it is

IGF-1 LR3 is a modified form of IGF-1 used by bodybuilders for muscle growth, as it stays active in the bloodstream longer than natural IGF-1. Research in animals covers cardiac growth, nerve regeneration, and Alzheimer's models. Not approved for human use; likely WADA-prohibited; evidence mostly from animal studies.

The scientific side

IGF-1 LR3 is a synthetic analogue of insulin-like growth factor-1 (IGF-1) that carries a substitution of arginine at position 3 and an N-terminal 13-amino-acid extension. Its defining pharmacological characteristic is markedly reduced affinity for IGF-binding proteins (IGFBPs) compared with native IGF-1, while retaining high affinity for the IGF-1 receptor (IGF-1R) (PMID 42395176; PMID 36091374; PMID 7683875). Because IGFBPs normally sequester IGF-1 and limit its bioavailability, LR3's low IGFBP affinity results in greater free-ligand availability and prolonged receptor signalling. Receptor binding activates downstream pathways including ERK and PI3K, and stimulates ERK1/2 phosphorylation in an N-glycosylation-dependent manner via IGF-1R. Downstream effects documented in research models include stimulation of cell proliferation, organ and skeletal muscle growth, myoblast proliferation, cardiomyocyte proliferation, and modulation of insulin secretion (PMID 33427051; PMID 19633297; PMID 12947030; PMID 33938236). LR3-IGF-1 is cleared more rapidly from wound fluid than native IGF-1 (half-life approximately 563 min in that model vs. 872 min for IGF-1), consistent with its reduced IGFBP association. LR3 does not bind IGFBP-3 or IGFBP-4, which distinguishes its pharmacology from native IGF-1 (PMID 8691093; PMID 11181549).

Class: IGF-1 analogue / Insulin-like growth factor analogue

Administration & storage

Administration
Intravenous infusion via surgically implanted fetal catheter (PMID: 33427051PMID: 39679943PMID: 33938236PMID: 37114757)Mini-osmotic pump / continuous subcutaneous infusion (PMID: 7683875PMID: 8053901PMID: 12067429)Subcutaneous injection (PMID: 18577570)Intranasal administration (PMID: 39610283)Local implant via hydrogel muscle void filler (PMID: 41418663)Serosal application to isolated tissue (in vitroPMID: 22227200)In vitro culture medium supplementation (multiple abstracts)
Storage
No storage conditions for IGF-1 LR3 are described in any of the reviewed abstracts. One abstract characterises physicochemical properties of LR3-IGF1 protein inclusion bodies (isoelectric point, electrophoretic mobility) relevant to manufacturing recovery processes, but not to end-user storage.
Cautions
No published human clinical trials or human pharmacokinetic/pharmacodynamic data for IGF-1 LR3 were identified in the reviewed abstracts; all dosing and safety data derive from animal and in vitro studies.,IGF-1 LR3 infusion in fetal sheep produced an intrinsic pancreatic islet defect with reduced glucose-stimulated insulin secretion and lower plasma insulin and glucose concentrations, raising concern for dysglycaemia.,LR3 IGF-I treatment was associated with accelerated tumour growth in a cancer cachexia mouse model, suggesting potential mitogenic risk in the context of pre-existing malignancy.,In tumour-bearing rats, LR3-IGF-I infusion decreased food intake, lowered insulin and glucose, and did not improve muscle protein accretion, raising concern about metabolic substrate depletion in catabolic states.,IGF-1 LR3 is classified in one narrative review among unregulated peptides lacking regulatory approval for performance or physique indications, with uncertainty around product composition, dose accuracy, and stacking practices in unregulated supply chains.,Sterile technique is essential for any injectable compound to prevent infection — this is a universal caution not specific to IGF-1 LR3.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification. One review notes absence of regulatory approval for physique- or performance-related indications and classifies IGF-1 LR3 among unregulated peptides…

WADA

Not stated in reviewed literature — requires manual verification.

Health Canada

Not stated in reviewed literature — requires manual verification.